Skip to main content

Advertisement

SpringerLink
Log in

DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Genes, active during normal development, are frequently reactivated during neoplastic transformation and may be related to progression. One of them, the transcription factor TP63, is crucial for pulmonary epithelial development and a possible target of the recurrent 3q amplifications in lung squamous cell carcinoma (SCC). Here, we explored whether TP63 reactivation could be associated to cancer progression in lung SCC through an epithelial to mesenchymal transition. We studied TP63 amplification and TP63 expression at RNA and protein levels and we analyzed the ΔNTP63/TATP63 ratio that quantifies the proportion of the isoform lacking the transactivation domain/the isoform containing the transactivation domain. We correlated TP63 status to survival and to the expression of epithelial (E-cadherin and plakoglobin) and mesenchymal (N-cadherin, vimentin, TWIST1, and SNAIL) markers. We found that high ΔN/TA TP63 ratio was related to high E-cadherin and plakoglobin mRNA levels (P < 0.05) and that E-cadherin mRNA level was the only marker related to survival. Kaplan–Meier survival curves stratified according to the expression level of E-cadherin showed, as already reported in breast cancer, that patients with low (first quartile) or high (last quartile) E-cadherin expression had a worse survival with respect to patients with intermediate E-cadherin expression. Altogether, our results indicate that a reactivation of ΔNTP63 is linked to the maintenance of epithelial markers and suggest that E-cadherin has a dual role in lung SCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.

    Article  PubMed  CAS  Google Scholar 

  2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.

    Article  PubMed  CAS  Google Scholar 

  3. Chujo M, Noguchi T, Miura T, Arinaga M, Uchida Y, Tagawa Y. Comparative genomic hybridization analysis detected frequent overrepresentation of chromosome 3q in squamous cell carcinoma of the lung. Lung Cancer. 2002;38:23–9.

    Article  PubMed  Google Scholar 

  4. Umayahara K, Numa F, Suehiro Y, Sakata A, Nawata S, Ogata H, et al. Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosomes Cancer. 2002;33:98–102.

    Article  PubMed  CAS  Google Scholar 

  5. Sattler HP, Lensch R, Rohde V, Zimmer E, Meese E, Bonkhoff H, et al. Novel amplification unit at chromosome 3q25–q27 in human prostate cancer. Prostate. 2000;45:207–15.

    Article  PubMed  CAS  Google Scholar 

  6. Lambros MB, Fiegler H, Jones A, Gorman P, Roylance RR, Carter NP, et al. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization. J Pathol. 2005;205:29–40.

    Article  PubMed  CAS  Google Scholar 

  7. Murata K, Ota S, Niki T, Goto A, Li CP, Ruriko UM, et al. P63—key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis. Exp Mol Pathol. 2007;83:367–76.

    Article  PubMed  CAS  Google Scholar 

  8. Qian J, Massion PP. Role of chromosome 3q amplification in lung cancer. J Thorac Oncol. 2008;3:212–5.

    Article  PubMed  Google Scholar 

  9. Finlan LE, Hupp TR. P63: the phantom of the tumor suppressor. Cell Cycle. 2007;6:1062–71.

    Article  PubMed  CAS  Google Scholar 

  10. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. P63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305–16.

    Article  PubMed  CAS  Google Scholar 

  11. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63:7113–21.

    PubMed  CAS  Google Scholar 

  12. Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, et al. P63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol. 2002;198:100–9.

    Article  PubMed  CAS  Google Scholar 

  13. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2009;101:293–9.

    Article  PubMed  Google Scholar 

  14. Herfs M, Hubert P, Suarez-Carmona M, Reschner A, Saussez S, Berx G, et al. Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma. Am J Pathol. 2010;176:1941–9.

    Article  PubMed  CAS  Google Scholar 

  15. Higashikawa K, Yoneda S, Tobiume K, Taki M, Shigeishi H, Kamata N. Snail-induced down-regulation of deltanp63alpha acquires invasive phenotype of human squamous cell carcinoma. Cancer Res. 2007;67:9207–13.

    Article  PubMed  CAS  Google Scholar 

  16. Gu X, Coates PJ, Boldrup L, Nylander K. P63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. Cancer Lett. 2008;263:26–34.

    Article  PubMed  CAS  Google Scholar 

  17. Higashikawa K, Yoneda S, Tobiume K, Saitoh M, Taki M, Mitani Y, et al. DeltaNp63alpha-dependent expression of Id-3 distinctively suppresses the invasiveness of human squamous cell carcinoma. Int J Cancer. 2009;124:2837–44.

    Article  PubMed  CAS  Google Scholar 

  18. Koster MI, Lu SL, White LD, Wang XJ, Roop DR. Reactivation of developmentally expressed p63 isoforms predisposes to tumor development and progression. Cancer Res. 2006;66:3981–6.

    Article  PubMed  CAS  Google Scholar 

  19. Lo Muzio L, Campisi G, Farina A, Rubini C, Pastore L, Giannone N, et al. Effect of p63 expression on survival in oral squamous cell carcinoma. Cancer Invest. 2007;25:464–9.

    Article  PubMed  CAS  Google Scholar 

  20. Morita M, Uramoto H, Nakata S, Ono K, Sugaya M, Yoshimatsu T, et al. Expression of deltanp63 in squamous cell carcinoma of the esophagus. Anticancer Res. 2005;25:3533–9.

    PubMed  CAS  Google Scholar 

  21. UICC. International Union Against Cancer: TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002.

    Google Scholar 

  22. Saviozzi S, Cordero F, Lo Iacono M, Novello S, Scagliotti GV, Calogero RA. Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer. BMC Cancer. 2006;6:200.

    Article  PubMed  Google Scholar 

  23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative pcr and the 2(−delta delta c(t)) method. Methods. 2001;25:402–8.

    Article  PubMed  CAS  Google Scholar 

  24. Blons H, Pallier K, Le Corre D, Danel C, Tremblay M, Houdayer C, et al. Genome wide snp comparative analysis between egfr and kras mutated nsclc and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. BMC Med Genomics. 2008;1:25.

    Article  PubMed  Google Scholar 

  25. World Health Organization classification of tumours. Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC, editors. Lyon: IARC Press; 2004.

  26. Westfall MD, Pietenpol JA. P63: molecular complexity in development and cancer. Carcinogenesis. 2004;25:857–64.

    Article  PubMed  CAS  Google Scholar 

  27. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. Sox2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010;5:e8960.

    Article  PubMed  Google Scholar 

  28. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15:6008–17.

    Article  PubMed  CAS  Google Scholar 

  29. Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, et al. Phosphatidylinositol 3′-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009;15:5724–32.

    Article  PubMed  CAS  Google Scholar 

  30. Lin SC, Liu CJ, Ko SY, Chang HC, Liu TY, Chang KW. Copy number amplification of 3q26–27 oncogenes in microdissected oral squamous cell carcinoma and oral brushed samples from areca chewers. J Pathol. 2005;206:417–22.

    Article  PubMed  CAS  Google Scholar 

  31. Jorda M, Gomez-Fernandez C, Garcia M, Mousavi F, Walker G, Mejias A, et al. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer Cytopathol. 2009;117:46–50.

    Article  Google Scholar 

  32. Redon R, Muller D, Caulee K, Wanherdrick K, Abecassis J, du Manoir S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: Pik3ca but not p63 gene as a likely target of 3q26-qter gains. Cancer Res. 2001;61:4122–9.

    PubMed  CAS  Google Scholar 

  33. Nylander K, Coates PJ, Hall PA. Characterization of the expression pattern of p63 alpha and delta np63 alpha in benign and malignant oral epithelial lesions. Int J Cancer. 2000;87:368–72.

    Article  PubMed  CAS  Google Scholar 

  34. Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol. 1999;113:1099–105.

    Article  PubMed  CAS  Google Scholar 

  35. Borrelli S, Candi E, Alotto D, Castagnoli C, Melino G, Vigano MA, et al. P63 regulates the caspase-8-flip apoptotic pathway in epidermis. Cell Death Differ. 2009;16:253–63.

    Article  PubMed  CAS  Google Scholar 

  36. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff E, Koch A, Schulze-Bergkamen H, et al. Tap63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 2005;24:2458–71.

    Article  PubMed  CAS  Google Scholar 

  37. Mundt HM, Stremmel W, Melino G, Krammer PH, Schilling T, Muller M. Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem Biophys Res Commun. 2010;396:335–41.

    Article  PubMed  CAS  Google Scholar 

  38. Harmes DC, Bresnick E, Lubin EA, Watson JK, Heim KE, Curtin JC, et al. Positive and negative regulation of deltan-p63 promoter activity by p53 and deltan-p63-alpha contributes to differential regulation of p53 target genes. Oncogene. 2003;22:7607–16.

    Article  PubMed  CAS  Google Scholar 

  39. Lena AM, Shalom-Feuerstein R, di Val R, Cervo P, Aberdam D, Knight RA, et al. Mir-203 represses ‘stemness’ by repressing deltanp63. Cell Death Differ. 2008;15:1187–95.

    Article  PubMed  CAS  Google Scholar 

  40. Craig AL, Holcakova J, Finlan LE, Nekulova M, Hrstka R, Gueven N, et al. DeltaNp63 transcriptionally regulates atm to control p53 serine-15 phosphorylation. Mol Cancer. 2010;9:195.

    Article  PubMed  Google Scholar 

  41. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–13.

    Article  PubMed  CAS  Google Scholar 

  42. Kommagani R, Leonard MK, Lewis S, Romano RA, Sinha S, Kadakia MP. Regulation of vdr by deltanp63alpha is associated with inhibition of cell invasion. J Cell Sci. 2009;122:2828–35.

    Article  PubMed  CAS  Google Scholar 

  43. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002;161:1199–206.

    Article  PubMed  CAS  Google Scholar 

  44. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. P63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004;18:126–31.

    Article  PubMed  CAS  Google Scholar 

  45. Maddau C, Confortini M, Bisanzi S, Janni A, Montinaro F, Paci E, et al. Prognostic significance of p53 and ki-67 antigen expression in surgically treated non-small cell lung cancer: immunocytochemical detection with imprint cytology. Am J Clin Pathol. 2006;125:425–31.

    PubMed  Google Scholar 

  46. Iwata T, Uramoto H, Sugio K, Fujino Y, Oyama T, Nakata S, et al. A lack of prognostic significance regarding deltanp63 immunoreactivity in lung cancer. Lung Cancer. 2005;50:67–73.

    Article  PubMed  Google Scholar 

  47. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006;12:7329–38.

    Article  PubMed  CAS  Google Scholar 

  48. Mauro LJ, Wenzel SJ, Sindberg GM. Regulation of chick bone growth by leptin and catecholamines. Poult Sci. 2010;89:697–708.

    Article  PubMed  CAS  Google Scholar 

  49. Querzoli P, Coradini D, Pedriali M, Boracchi P, Ambrogi F, Raimondi E, et al. An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. Br J Cancer. 2010;103:1835–9.

    Article  PubMed  CAS  Google Scholar 

  50. Miao Y, Liu N, Zhang Y, Liu Y, Yu JH, Dai SD, et al. P120ctn isoform 1 expression significantly correlates with abnormal expression of E-cadherin and poor survival of lung cancer patients. Med Oncol. 2010;27:880–6.

    Article  PubMed  CAS  Google Scholar 

  51. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of e-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res. 2000;6:4789–96.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work is part of the national program Cartes d’Identité des Tumeurs ® (CIT) http://cit.ligue-cancer.net/ which is funded and developed by the Ligue Nationale Contre le Cancer. Grant support was provided by INCA Institute (Institut du Cancer), grant 09004CP.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. UMR-S775, INSERM, 45 Rue des Saints Pères, Paris, 75006, France

    Karine Pallier

  2. Paris Descartes University, Paris, 75006, France

    Karine Pallier, Pierre Laurent-Puig & Hélène Blons

  3. AP-HP Department of Pathology, European Georges Pompidou Hospital, Paris, 75015, France

    Aurélie Cazes

  4. AP-HP Department of Biology, AP-HP European Georges Pompidou Hospital, Paris, 75015, France

    Laila El Khattabi, Cristina Lecchi, Marine Desroches, Pierre Laurent-Puig & Hélène Blons

  5. AP-HP Department of Pathology, APHP Bichat Hospital, Paris, 75018, France

    Claire Danel

  6. AP-HP Department of Thoracic Surgery, European Georges Pompidou Hospital, AP-HP, Paris, 75015, France

    Marc Riquet

  7. AP-HP Department of Oncology, Hôpital Européen Georges Pompidou, Paris, 75015, France

    Elizabeth Fabre-Guillevin

  8. UMR-S775, INSERM, Paris, 75006, France

    Pierre Laurent-Puig

  9. UMR775, INSERM, 45 Rue des Saints Pères, 75006, Paris, France

    Hélène Blons

Authors
  1. Karine Pallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aurélie Cazes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laila El Khattabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cristina Lecchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marine Desroches
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claire Danel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marc Riquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Elizabeth Fabre-Guillevin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pierre Laurent-Puig
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hélène Blons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hélène Blons.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Table 1

(XLS 24 kb)

Supplementary Table 2

Relative expression of CDH1, JUP, DN/TA TP63 ratio, CDH2, VIM, and TWIST according to non-tumor lung tissue in each SCC sample. (DOC 164 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pallier, K., Cazes, A., El Khattabi, L. et al. DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma. Tumor Biol. 33, 41–51 (2012). https://doi.org/10.1007/s13277-011-0239-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-011-0239-5

Keywords

Search

Navigation